DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

Phase 1

Terminated

Conditions: Colorectal Neoplasms Malignant

Interventions: Drug: Axitinib 5 MG
Drug: Hydroxychloroquine Pill
Procedure: trans arterial chemoembolization

First Posted Date: 2021-05-05

Last Posted Date: 2024-04-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 5

Registration Number: NCT04873895

Locations: 🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Effect of Behavioral Nudges on Serious Illness Conversation Documentation

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: Usual Care
Other: Clinician Nudge
Other: Patient Nudge

First Posted Date: 2021-04-30

Last Posted Date: 2024-04-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 4450

Registration Number: NCT04867850

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

Telehealth Weight Loss Program for Breast Cancer Survivors

Not Applicable

Active, not recruiting

Conditions: Body Weight
Cancer Survivors
Cancer of Breast
Overweight and Obesity

Interventions: Behavioral: Behavioral Weight-loss Program Via Telehealth
Behavioral: Behavioral Weight-Loss Program Via Telehealth - Weight Measures
Behavioral: Validated Surveys of Patient-Reported Outcomes

First Posted Date: 2021-04-22

Last Posted Date: 2023-08-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 22

Registration Number: NCT04855552

Locations: 🇺🇸
University of Pennsylvania (Hospital of the University of Pennsylvania), Philadelphia, Pennsylvania, United States

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts

Recruiting

Conditions: Breast Diseases

First Posted Date: 2021-04-22

Last Posted Date: 2024-08-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 500

Registration Number: NCT04854304

Locations: 🇺🇸
UPENN, Philadelphia, Pennsylvania, United States

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: HCQ
Drug: Avelumab
Drug: Palbociclib

First Posted Date: 2021-04-12

Last Posted Date: 2025-03-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 96

Registration Number: NCT04841148

Locations: 🇺🇸
Georgetown University, Washington, DC, District of Columbia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

and more 4 locations

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Phase 2

Recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2021-04-01

Last Posted Date: 2025-01-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT04827862

Locations: 🇺🇸
Abamson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches

Not Applicable

Completed

Conditions: Cigarette Smoking Behavior

Interventions: Other: Culturally tailored anti-smoking messages
Other: Non-culturally tailored interventions

First Posted Date: 2021-03-24

Last Posted Date: 2023-11-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 2214

Registration Number: NCT04812795

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

Not Applicable

Active, not recruiting

Conditions: Smoking Cessation

Interventions: Behavioral: Removal of Financial Barriers
Behavioral: Financial Incentives
Behavioral: Mobile Health Application

First Posted Date: 2021-03-15

Last Posted Date: 2024-12-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 3228

Registration Number: NCT04798664

Locations: 🇺🇸
Lancaster General Health, Lancaster, Pennsylvania, United States
🇺🇸
Kaiser Permanente Southern California, Oakland, California, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 2 locations

Multimodality MRI and Liquid Biopsy in GBM

Early Phase 1

Withdrawn

Conditions: Brain Tumor, Primary
Glioblastoma Multiforme
Brain Tumor, Adult: Glioblastoma
Brain Tumor, Recurrent

Interventions: Diagnostic Test: Post Feraheme Infusion MRI

First Posted Date: 2021-03-02

Last Posted Date: 2022-09-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT04776980

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes

Not Applicable

Active, not recruiting

Conditions: Genetic Predisposition
Cancer

Interventions: Behavioral: MyCancerGene

First Posted Date: 2021-03-01

Last Posted Date: 2025-02-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 400

Registration Number: NCT04774445

Locations: 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy